A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA

Table 6

Change from baseline in WOMAC pain score.

Visits	Curene® 500mg		Placebo
	N=25		N=25
	Mean (SD)	Change from baseline	Mean (SD)	Change from baseline
Baseline (Day 0)	8.24±1.56		8.16±1.21
Visit 2 (Day 7)	7.36±1.73	0.88±0.44	8±1.12	0.16±1.03
Visit 3 (Day 15)	6.6±1.66	1.64±0.64	7.64±0.91	0.52±1.16
Visit 4 (Day 30)	5.8±1.80	2.44±0.72	7.32±1.07	0.84±1.25
Visit 5 (Day 60)	4.28±1.54	3.96±1.06	6.96±1.43	1.2±1.44

Statistically significant (P <0.05) within group; statistically significant (P <0.05) between group.
Within group analysis by Pair t-test and between group analysis by repeated measures ANCOVA.